Lenz & Staehelin advised Chord Therapeutics in its Series A financing
Chord Therapeutics, a Geneva clinical stage biopharmaceutical company developing drugs for rare diseases, announced the closing of a USD 16 million Series A financing from leading healthcare investor Omega Funds. The financing will allow the company to progress its lead drug candidate, CRD1, a small molecule oral drug for the treatment of neuromyelitis optica spectrum disorders, through Phase 2 proof of concept clinical development.